Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants

被引：0
|
作者：
Romain Sechaud
Helen Gu
Gholamreza Rahmanzadeh
Amanda Taylor
Ovidiu Chiparus
Gopal Krishna Sharma
Astrid Breitschaft
Hans D. Menssen
机构：
[1] Novartis Pharma AG,
[2] Novartis Pharmaceuticals Corporation,undefined
[3] Novartis Healthcare Pvt. Ltd.,undefined
[4] Parexel International GmbH,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2024年 / 93卷
关键词：
Midostaurin; Drug–drug interaction; Midazolam; Bupropion; Pioglitazone; Oral contraceptive;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：439 / 453
页数：14
相关论文
共 50 条
  • [41] Drug metabolism of CYP3A4, CYP2C9 and CYP2D6 substrates in pigs and humans
    Thorn, Helena Anna
    Lundahl, Anna
    Schrickx, Johannes Antonius
    Dickinson, Paul Alfred
    Lennernas, Hans
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2011, 43 (03) : 89 - 98
  • [42] Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam
    M. I. Veiga
    S. Asimus
    P. E. Ferreira
    J. P. Martins
    I. Cavaco
    V. Ribeiro
    T. N. Hai
    M. G. Petzold
    A. Björkman
    M. Ashton
    J. P. Gil
    European Journal of Clinical Pharmacology, 2009, 65 : 355 - 363
  • [43] Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam
    Veiga, M. I.
    Asimus, S.
    Ferreira, P. E.
    Martins, J. P.
    Cavaco, I.
    Ribeiro, V.
    Hai, T. N.
    Petzold, M. G.
    Bjorkman, A.
    Ashton, M.
    Gil, J. P.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 65 (04) : 355 - 363
  • [44] Plausible drug interaction between cyclophosphamide and voriconazole via inhibition of CYP2B6
    Shibata, Yukihiro
    Tamemoto, Yuta
    Singh, Sheelendra Pratap
    Yoshitomo, Aoi
    Hozuki, Shizuka
    Sato, Hiromi
    Hisaka, Akihiro
    DRUG METABOLISM AND PHARMACOKINETICS, 2021, 39
  • [45] Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A activity) during pregnancy
    Tracy, TS
    Venkataramanan, R
    Glover, DD
    Caritis, SN
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2005, 192 (02) : 633 - 639
  • [46] Pharmacokinetic Evaluation of the CYP3A4 and CYP2C9 Drug-Drug Interaction of Avacopan in 2 Open-Label Studies in Healthy Participants
    Miao, Shichang
    Bekker, Pirow
    Armas, Danielle
    Lor, Mary
    Han, Yanyan
    Webster, Kenneth
    Trivedi, Ashit
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2024, 13 (05): : 517 - 533
  • [47] Association of CYP2B6, CYP3A5, and CYP2C19 Genetic Polymorphisms With Sibutramine Pharmacokinetics in Healthy Korean Subjects
    Kim, K. A.
    Song, W. K.
    Park, J. Y.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 86 (05) : 511 - 518
  • [48] RNA Editing Enzymes Modulate the Expression of Hepatic CYP2B6, CYP2C8, and Other Cytochrome P450 Isoforms
    Nozaki, Kaori
    Nakano, Masataka
    Iwakami, Chika
    Fukami, Tatsuki
    Nakajima, Miki
    DRUG METABOLISM AND DISPOSITION, 2019, 47 (06) : 639 - 647
  • [49] EIDD-1931 Treatment Tweaks CYP3A4 and CYP2C8 in Arthritic Rats to Expedite Drug Interaction: Implication in Oral Therapy of Molnupiravir
    Bhardwaj, Mahir
    Kour, Dilpreet
    Rai, Garima
    Bhattacharya, Srija
    Manhas, Diksha
    Vij, Bhavna
    Kumar, Ajay
    Mukherjee, Debaraj
    Ahmed, Zabeer
    Gandhi, Sumit G.
    Nandi, Utpal
    ACS OMEGA, 2024, 9 (12): : 13982 - 13993
  • [50] Effect of midostaurin on the pharmacokinetics of P-gp, BCRP, and CYP2D6 substrates: assessing potential drug-drug interactions in healthy participants
    Sechaud, Romain
    Gu, Helen
    Rahmanzadeh, Gholamreza
    Chiparus, Ovidiu
    Breitschaft, Astrid
    Menssen, Hans D.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 94 (04) : 535 - 547
12345